Welcome to our dedicated page for Radnostix news (Ticker: INIS), a resource for investors and traders seeking the latest updates and insights on Radnostix stock.
Radnostix, Inc. manufactures radioisotope-focused products for medical, industrial and research applications and trades on the OTCQB under INIS. The company, formerly International Isotopes Inc., supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer, provides contract drug manufacturing and radioisotope API supply for theranostics clients, and sells calibration and reference standards for nuclear pharmacies, SPECT/PET imaging systems and industrial users through RadQual.
Recurring updates cover operating and financial results across Theranostics Products, Calibration & Reference Products, Nuclear Medicine Standards, Medical Devices and Cobalt Products, along with raw-material supply conditions, product-line updates for EasyFill and RadVent, and the completed corporate rebrand to Radnostix.
International Isotopes Inc. (OTCQB: INIS) has announced an exclusive licensing agreement with Memorial Sloan Kettering Cancer Center for a radiolabeled antibody test to detect SARS-CoV-2. This test, which is inexpensive and portable, showed promising efficacy in detecting the virus at concentrations as low as 19700 PFU/mL. The testing procedure is rapid and non-invasive, requiring only a small saliva sample. The agreement allows INIS exclusive rights to commercialize the invention, with plans for potential testing on other viruses. CEO Steve Laflin expressed optimism about the test's future applications.
International Isotopes Inc. (OTCQB: INIS) reported its financial results for Q3 and nine months ended September 30, 2021. Q3 revenue decreased to $2,617,514 from $2,864,288 in 2020, while nine-month revenue slightly rose to $7,369,922 from $7,359,633. Operating expenses escalated over 14% due to increased depreciation from a new manufacturing facility. The company faced a net loss of $136,869 for Q3 and $919,408 for the nine months. Despite COVID-19 impacts, revenue for nuclear medicine products grew, attributed to the acquisition of RadQual LLC, which is expected to enhance future performance.
International Isotopes Inc. (OTCQB: INIS) reported a revenue of $2,759,896 for the second quarter of 2021, marking a 28% increase compared to $2,159,559 in Q2 2020. The revenue growth stemmed from higher sales in radiochemical products, cobalt products, and nuclear medicine standards, leading to an operating income of $14,722 versus a loss of $96,101 in the prior year. Notable increases included a 157% rise in cobalt product sales, aided by restored access to DOE resources, and a 14% growth in nuclear medicine sales.
International Isotopes Inc. (OTCQB: INIS) announced the acquisition of the remaining 75% of RadQual LLC, making it a wholly-owned subsidiary. This strategic move, executed through common shares, is valued at eight times projected earnings for the year, aiming to enhance shareholder equity and net profit margins. RadQual specializes in quality control products for nuclear medicine, particularly SPECT and PET imaging. This acquisition is expected to strengthen INIS's market position and potentially facilitate a listing on a major exchange in the future.
International Isotopes Inc. (OTCQB: INIS) reported a revenue of $1,992,512 for Q1 2021, marking a 15% decline from $2,335,786 in Q1 2020. The company faced a net loss of $601,152, up from $422,494 last year. The drop in revenue was primarily due to reduced sales in radiochemical and cobalt products, alongside higher operational costs. However, revenue from nuclear medicine products rose by 8%, attributed to recovering demand as COVID-19's impact diminishes. Management anticipates growth in radiochemical and cobalt segments moving forward.
International Isotopes (OTCQB: INIS) reported a net income of approximately $2.2 million for the year ended December 31, 2020, reversing a net loss of about $1.5 million in 2019. Total revenues rose to $9.3 million, a 5% increase from $8.9 million in 2019, driven by strong sales in the radiochemical and cobalt segments. The company achieved FDA approval for its sodium iodide I-131 product, resulting in a 43% revenue increase in the radiochemical sector. Significant improvements in liquidity were noted, with a 50% reduction in accounts payable.
International Isotopes Inc. (OTCQB: INIS) announced that its subsidiary RadQual has partnered with LEA for the distribution of calibration and reference sources in North America. LEA's products are globally recognized for their quality and are measured under the ISO 17025:2017 standard. This agreement will allow RadQual to import and distribute these high-value calibration sources across the U.S. and Canada, enhancing their product offerings in the nuclear medicine sector. This partnership is expected to provide customers with an alternative supply of high-quality products and improved service.
International Isotopes Inc. (OTCQB: INIS) reported financial results for Q2 and the first half of 2020. Q2 revenue rose by 1% to $2,159,559, but six-month revenue fell 4% to $4,495,345 due to COVID-19 impacts. Gross profit increased by 8% for Q2 and 1% for H1. Operating expenses rose by 8% in Q2 and 15% in H1, driven by staffing for new product development. Notable is a net income of $229,328 in Q2, up from a net loss of $1,157,194 in 2019. However, revenue from nuclear medicine products and radiological services decreased significantly due to the pandemic.